# EDGAR Filing Document

**Accession Number:** 0001604924
**File Stem:** 0001171843-23-000290
**Filing Date:** 2023-1
**Character Count:** 2721
**Document Hash:** 8718dca5a03415962957c6bc1d3c27ce
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-23-000290.hdr.sgml**: 20230117

**ACCESSION NUMBER**: 0001171843-23-000290

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230117

**DATE AS OF CHANGE**: 20230117

**EFFECTIVENESS DATE**: 20230117

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Forward Pharma A/S
- **CENTRAL INDEX KEY:** 0001604924
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** G7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36686
- **FILM NUMBER:** 23530262

**BUSINESS ADDRESS:**
- **STREET 1:** OSTERGADE 24A, 1
- **CITY:** COPENHAGEN
- **STATE:** G7
- **ZIP:** 1100
- **BUSINESS PHONE:** 0114533444242

**MAIL ADDRESS:**
- **STREET 1:** OSTERGADE 24A, 1
- **CITY:** COPENHAGEN
- **STATE:** G7
- **ZIP:** 1100

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 15** 

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION** 

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)** 

**OF THE SECURITIES EXCHANGE ACT OF 1934.** 

Commission File Number: 001-36686

## Forward Pharma A/S
(Exact name of registrant as specified in its charter)

**Østergade 24A, 1st Floor**

**1100 Copenhagen K, Denmark**

**Tel: +45 3344 4242**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Ordinary shares, nominal value DKK 0.01 per share<br> American Depositary Shares, each representing 14 ordinary shares**

(Title of each class of securities covered by this Form)

**None**

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ☒ |
| Rule 12g-4(a)(2) | ☐ |
| Rule 12h-3(b)(1)(i) | ☒ |
| Rule 12h-3(b)(1)(ii) | ☐ |
| Rule 15d-6 | ☐ |
| Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: 6

Pursuant to the requirements of the Exchange Act, Forward has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
|  | **Forward Pharma A/S** | **Forward Pharma A/S** |
| Date: January 17, 2023 | By: | /s/ Claus Bo Svendsen |
|  | Name: | Claus Bo Svendsen |
|  | Title: | Chief Executive Officer |

---

------